IMMUTEP Ltd
Close on Oct 19, 2026
About Immutep
Pharmaceutical Preparations, SIC 2834
Immutep is an entity engaged in research and development activities focused on clinical trials, contract research, and contract manufacturing operations. The organization conducts ongoing clinical trials and collaborates with external vendors and specialized research organizations to advance its clinical trial programs and evaluate its scientific developments across its operating segments.
The group maintains an international geographic footprint through operational subsidiaries across several territories, including Immutep SAS in France, Immutep GmbH in Germany, Immutep USA Inc. in the United States, Immutep Australia Pty Ltd in Australia, and PRR Middle East FZ LLC. The provided excerpt does not identify the company's designated headquarters location.
Summary of the business section of Immutep's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IMMUTEP Ltd
- Headquarters
- Sydney,, C3
- Address
- Level 32, Suite 32.07 Australia Square, 264 George Street NSW 2000
- Phone
- 612 8315 7003
- Employees
- 51, Jun 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- PricewaterhouseCoopers, Sydney, Australia
Stock & identifiers
- Ticker
- IMMP
- Other tickers
- PRRUF
- Exchange
- Nasdaq
- Shares outstanding
- 1.46B, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 1-for-20 reverse, Sep 28, 2026; 1-for-9.5 reverse, Sep 25, 2020; 1-for-3.33 reverse, Dec 28, 2016
- SEC CIK
- 1506184
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marc Voigt | See Remarks, Director | 85,700 |
| Deanne Diem Miller | Chief Operating Officer | 2,867,305 |
| Christian Mueller | Chief Development Officer | 3,774,048 |
| Stephan Karel Gerard Winckels | Chief Medical Officer | 92,935 |
| Elisabeth Amanda Boyce | Director | 423,288 |
| Pete A. Meyers | Director | 4,052,173 |
| Frederic Joseph Daniel Triebel | Director | 170,610 |
| Russell J. Howard | Director | 1,717,977 |
Employees
Headcount reported in annual reports
“As of June 30, 2025, we employed 51 people.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 1, 2017 | Name change | Name changed from Prima BioMed Ltd to IMMUTEP Ltd |